Opportunity Information: Apply for RFA AI 23 020
The NIH funding opportunity RFA AI 23 020 supports the creation of Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers focused on three virus groupings with recognized pandemic potential: Bunyavirales, Paramyxoviridae, and Picornaviridae. The intent is to build comprehensive, cooperative research centers that combine basic and translational science to do deep, coordinated work on selected prototype viruses within these families. Rather than treating each emerging virus as a one-off crisis, the program is designed around the idea that viruses within the same family often share structural and functional features, so a strategy proven against a representative prototype can be adapted more quickly to related threats when an outbreak happens.
The central scientific deliverable is the development of vaccine and monoclonal antibody strategies that are broadly useful within a virus family. Applicants are expected to choose prototype pathogen(s) within the eligible families and generate knowledge and product-enabling tools that can transfer to close relatives, accelerating preparedness. In practical terms, this points to work such as identifying conserved viral targets, characterizing immune responses, defining correlates of protection, designing and optimizing immunogens, and advancing monoclonal antibody discovery and characterization. The emphasis on centers signals that NIH is looking for integrated capabilities (for example, virology, immunology, structural biology, antigen design, antibody engineering, and relevant translational pipelines) operating in a coordinated way, either within a single institution or across a consortium.
The award mechanism is a cooperative agreement (U19), which typically means the NIH will have substantial programmatic involvement compared with a standard research grant. The program is positioned as a network (the ReVAMPP Network), so funded centers are expected to function as part of a broader, coordinated effort rather than as isolated projects. The FOA explicitly states "Clinical Trial Not Allowed," indicating that proposed activities must not include clinical trials; the work should remain in preclinical or other non-clinical-trial domains consistent with basic and translational research leading up to, but not including, human efficacy testing.
Administratively, the opportunity is categorized as discretionary health funding under CFDA 93.855, administered by the National Institutes of Health. The instrument type is a cooperative agreement, and the posted award ceiling is $10,000,000. The original closing date listed is 2023-06-08, and the FOA was created on 2023-03-16. The funding opportunity title makes clear that the centers are specifically for vaccine and monoclonal antibody R and D aimed at pandemic preparedness for the named virus families.
Eligibility is broad and includes many types of domestic U.S. applicants: state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations (other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, and non-domestic (non-U.S.) entities/foreign organizations as well as regional organizations. This wide eligibility aligns with the network concept and encourages diverse institutional participation, including consortia that can assemble the specialized expertise and infrastructure needed for advanced vaccine and monoclonal antibody development work.
Overall, this FOA is about standing up coordinated, center-based research programs that can generate platform-like vaccine and antibody approaches for high-risk virus families, so that when a new related virus emerges, the scientific groundwork and candidate countermeasure strategies are already in place and can be adapted quickly.Apply for RFA AI 23 020
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2023-03-16.
- Applicants must submit their applications by 2023-06-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $10,000,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Health
Next opportunity: Notice of Intent (NOI) related to Regional Initiative for Technical Assistance Partnerships (RITAP) to Advance Deployment of Basin-Scale Carbon Transport and Storage and Community Engagement
Previous opportunity: NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 23 020
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 23 020) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed) Apply for RFA AI 23 019 Funding Number: RFA AI 23 019 Agency: National Institutes of Health Category: Health Funding Amount: $10,000,000 |
| NIH Administrative Supplements to Recover Losses due to Hurricanes Fiona and Ian Under the Consolidated Appropriations Act, 2023 (Admin Supp Clinical Trial Optional) Apply for PA 23 134 Funding Number: PA 23 134 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional) Apply for RFA MH 23 140 Funding Number: RFA MH 23 140 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed) Apply for PAR 23 138 Funding Number: PAR 23 138 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Institutional AD/ADRD Research Training Program (T32 Clinical Trial Not Allowed) Apply for PAR 23 113 Funding Number: PAR 23 113 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Molecular Transducers of Physical Activity Chemical Analysis Sites (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 009 Funding Number: RFA RM 23 009 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Limited Competition: Molecular Transducers of Physical Activity Bioinformatics Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 008 Funding Number: RFA RM 23 008 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Limited Competition: Molecular Transducers of Physical Activity Consortium Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 011 Funding Number: RFA RM 23 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Molecular Transducers of Physical Activity Clinical Centers (U01 Clinical Trial Required) Apply for RFA RM 23 010 Funding Number: RFA RM 23 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Defining Mechanisms of HIV Induced Inflammation and Immune Activation During Suppressive Antiretroviral Therapy (ART) (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 018 Funding Number: RFA AI 23 018 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integration and Coordination Center for the Common Fund Data Ecosystem (U54 Clinical Trial Not Allowed) Apply for RFA RM 23 002 Funding Number: RFA RM 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors Transformative Research Awards (R01 Clinical Trial Optional) Apply for RFA RM 23 006 Funding Number: RFA RM 23 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional) Apply for RFA MH 23 260 Funding Number: RFA MH 23 260 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| NIH Directors Early Independence Awards (DP5 Clinical Trial Optional) Apply for RFA RM 23 007 Funding Number: RFA RM 23 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional) Apply for RFA NS 23 021 Funding Number: RFA NS 23 021 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) Apply for RFA RM 23 005 Funding Number: RFA RM 23 005 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed) Apply for PAR 23 132 Funding Number: PAR 23 132 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Animal Models for Hepatitis B and C (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 022 Funding Number: RFA AI 23 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed) Apply for PAR 23 133 Funding Number: PAR 23 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional) Apply for RFA NS 23 022 Funding Number: RFA NS 23 022 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 23 020", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.